Eric Floyd, PhD

Chief Regulatory & Quality Officer

Eric Floyd serves as Chief Regulatory & Quality Officer. He joined 4DMT in September 2026. He has spent the past nearly 30 years working across all aspects of global drug development, with a focus on regulatory strategy and quality for gene therapy, CNS/neurology, oncology, and rare disease programs.

Prior to joining 4DMT, Dr. Floyd served as Chief Regulatory and Quality Officer at Silence Therapeutics for six years (acquired by Merck KGaA). Previously, Dr. Floyd was Chief Regulatory Officer at Neurogene, Inc., where he led regulatory strategy for the company’s AAV pediatric gene therapy portfolio. Over a career that has spanned roles from Associate Director to Chief Regulatory Officer, he has held regulatory leadership positions at Hospira, Cephalon, Novartis, and Merck, contributing to more than 30 global approvals and building regulatory frameworks for AAV gene therapy and Schedule II REMS programs. He has deep expertise in expedited FDA pathways — Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval — and in IND/NDA/BLA submissions across the FDA, EMA, MHRA, and PMDA.

Dr. Floyd received his BS in Biology from the University of Illinois at Urbana-Champaign, MS In Neuroscience from Tennessee State University, PhD in Neurophysiology from Meharry Medical College, and an Executive MBA in Pharmaceutical Marketing and Healthcare from Saint Joseph’s University.